<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Central Drugs Standard Control Organization</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Self-amplifying mRNA technology underscored for next big pandemic</title>
      <description>
        <![CDATA[Experts in mRNA convened at the Global Vaccine Forum (GVF) 2025 to weigh the present and future of vaccine technology, including emerging innovations in self-amplifying mRNA (sa-mRNA) and drug delivery platforms. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/721835</guid>
      <pubDate>Tue, 01 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721835-self-amplifying-mrna-technology-underscored-for-next-big-pandemic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Vaccineforum-IVI-directorgeneral-Jerome-KIM-6-27-hero.webp?t=1751053811" type="image/jpeg" medium="image" fileSize="538538">
        <media:title type="plain">Jerome Kim, of IVI, speaking at the Global Vaccine Forum</media:title>
        <media:description type="plain">Jerome Kim, director-general, IVI</media:description>
      </media:content>
    </item>
    <item>
      <title>Self-amplifying mRNA technology underscored for next big pandemic</title>
      <description>
        <![CDATA[Experts in mRNA convened at the Global Vaccine Forum (GVF) 2025 to weigh the present and future of vaccine technology, including emerging innovations in self-amplifying mRNA (sa-mRNA) and drug delivery platforms. “Breakthroughs in mRNA and next-generation vaccine platforms are revolutionizing how we prepare for and respond to global health challenges,” Jerome H. Kim, International Vaccine Institute (IVI) director general, told the audience in Seoul, South Korea, June 19.]]>
      </description>
      <guid>http://www.bioworld.com/articles/721529</guid>
      <pubDate>Fri, 27 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/721529-self-amplifying-mrna-technology-underscored-for-next-big-pandemic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Vaccineforum-IVI-directorgeneral-Jerome-KIM-6-27-hero.webp?t=1751053811" type="image/jpeg" medium="image" fileSize="538538">
        <media:title type="plain">Jerome Kim, of IVI, speaking at the Global Vaccine Forum</media:title>
        <media:description type="plain">Jerome Kim, director-general, IVI</media:description>
      </media:content>
    </item>
    <item>
      <title>Immunoact lays groundwork for India cell, gene therapy innovation</title>
      <description>
        <![CDATA[India’s first indigenous CAR T therapy is selling at around $50,000 per shot, nearly one-tenth of the price of top-selling CAR Ts in the U.S., and Immunoact founder and CEO Rahul Purwar told <em>BioWorld</em> he anticipates bringing the price down to as low as $20,000 per shot.]]>
      </description>
      <guid>http://www.bioworld.com/articles/710608</guid>
      <pubDate>Tue, 16 Jul 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710608-immunoact-lays-groundwork-for-india-cell-gene-therapy-innovation</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2024/Rahul-Purwar-founder-and-CEO-Immunoact-7-16.webp?t=1721157574" type="image/jpeg" medium="image" fileSize="168594">
        <media:title type="plain">Rahul Purwar, founder and CEO, Immunoact</media:title>
        <media:description type="plain">Rahul Purwar, founder and CEO, Immunoact</media:description>
      </media:content>
    </item>
    <item>
      <title>India launches Immunoact’s homegrown NexCAR19 for cancer</title>
      <description>
        <![CDATA[India’s first indigenous CAR T therapy is expected to cost around $50,000, nearly one-tenth of the price of top-selling CAR Ts in the U.S. India President Droupadi Murmu officially launched Immunoadoptive Cell Therapy’s (Immunoact) NexCAR19 (actalycabtagene autoleucel), a CD19-targeted CAR T, and dedicated it to the nation in April 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708611</guid>
      <pubDate>Tue, 14 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708611-india-launches-immunoacts-homegrown-nexcar19-for-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2024/Indian-President-Droupadi-Murmu-5-8-.webp?t=1715196927" type="image/jpeg" medium="image" fileSize="218077">
        <media:title type="plain">Indian President Droupadi Murmu</media:title>
        <media:description type="plain">Indian President Droupadi Murmu officially launched India’s first homegrown CAR T therapy in April 2024. Credit: Press Information Bureau, Government of India.</media:description>
      </media:content>
    </item>
    <item>
      <title>India launches Immunoact’s homegrown NexCAR19 for cancer</title>
      <description>
        <![CDATA[India’s first indigenous CAR T therapy is expected to cost around $50,000, nearly one-tenth of the price of top-selling CAR Ts in the U.S. India President Droupadi Murmu officially launched Immunoadoptive Cell Therapy’s (Immunoact) NexCAR19 (actalycabtagene autoleucel), a CD19-targeted CAR T, and dedicated it to the nation in April 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/708409</guid>
      <pubDate>Wed, 08 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708409-india-launches-immunoacts-homegrown-nexcar19-for-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2024/Indian-President-Droupadi-Murmu-5-8-.webp?t=1715196927" type="image/jpeg" medium="image" fileSize="218077">
        <media:title type="plain">Indian President Droupadi Murmu</media:title>
        <media:description type="plain">Indian President Droupadi Murmu officially launched India’s first homegrown CAR T therapy in April 2024. Credit: Press Information Bureau, Government of India.</media:description>
      </media:content>
    </item>
    <item>
      <title>India moves forward with risk classification for devices, stronger regulation</title>
      <description>
        <![CDATA[Through a series of notifications, India’s drug regulator has classified a new batch of medical devices as well as a range of software used in medical devices according to risk, taking another step to strengthen regulatory oversight and shore up the domestic med-tech sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512083</guid>
      <pubDate>Tue, 05 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512083-india-moves-forward-with-risk-classification-for-devices-stronger-regulation</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/India/asia-india-flag.webp?t=1588688474" type="image/png" medium="image" fileSize="407500">
        <media:title type="plain">Flag of India</media:title>
      </media:content>
    </item>
    <item>
      <title>India begins approving long list of banned FDC drugs</title>
      <description>
        <![CDATA[India’s drug regulator has approved 31 fixed-dose combination (FDC) drugs out of more than 300 banned products, after an assessment by its drugs technical advisory board. It has also asked for more phase IV postmarketing data for 19 others.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511151</guid>
      <pubDate>Tue, 07 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511151-india-begins-approving-long-list-of-banned-fdc-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/India/India-pill-bottle-drugs.webp?t=1588688457" type="image/png" medium="image" fileSize="125387">
        <media:title type="plain">Pill bottle with flag of India</media:title>
      </media:content>
    </item>
    <item>
      <title>Regulatory front for Dec. 29, 2020</title>
      <description>
        <![CDATA[The latest global regulatory news, changes and updates affecting medical devices and technologies, including: U.S. FDA provides updates on power morcellation; FDA seeks nominations for advisory committee; CDSCO suspends import notification requirements.]]>
      </description>
      <guid>http://www.bioworld.com/articles/501870</guid>
      <pubDate>Tue, 29 Dec 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/501870-regulatory-front-for-dec-29-2020</link>
    </item>
    <item>
      <title>India extends med-tech registration deadline amidst regulations scramble</title>
      <description>
        <![CDATA[HONG KONG &ndash; Indian authorities have apparently given medical device manufacturers a one-year extension to register for market authorization that was originally to be done by the New Year. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/432368</guid>
      <pubDate>Mon, 13 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432368-india-extends-med-tech-registration-deadline-amidst-regulations-scramble</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/India/asia-india-flag.webp?t=1588688474" type="image/png" medium="image" fileSize="407500">
        <media:title type="plain">Flag of India</media:title>
      </media:content>
    </item>
  </channel>
</rss>
